LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 142

Search options

  1. Article: ANCA Associated Vasculitis Subtypes: Response [Letter].

    Merkel, Peter A / Jayne, David R W / Bekker, Pirow

    Journal of inflammation research

    2022  Volume 15, Page(s) 5161–5162

    Language English
    Publishing date 2022-09-09
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2494878-0
    ISSN 1178-7031
    ISSN 1178-7031
    DOI 10.2147/JIR.S385293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Glomerular basement membrane nephritis: crescentic renal inflammation and immunosuppressive intervention in the time of the severe acute respiratory syndrome coronavirus 2 pandemic.

    Brix, Silke R / Jones, Rachel B / Jayne, David R W

    Kidney international

    2021  Volume 99, Issue 5, Page(s) 1234–1235

    MeSH term(s) Basement Membrane ; COVID-19 ; Glomerular Basement Membrane ; Glomerulonephritis ; Humans ; Inflammation ; Nephritis ; Pandemics ; SARS-CoV-2
    Language English
    Publishing date 2021-02-11
    Publishing country United States
    Document type Letter
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2021.02.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Estimating the epidemiology of anti-neutrophil cytoplasm antibody-associated renal vasculitis and the role of histologic chronicity in predicting renal outcomes.

    Kronbichler, Andreas / Jayne, David R W

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2019  Volume 34, Issue 9, Page(s) 1429–1432

    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ; Antibodies, Antineutrophil Cytoplasmic ; Cytoplasm ; Glomerulonephritis ; Humans ; Incidence ; Prevalence
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic
    Language English
    Publishing date 2019-02-19
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfy402
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Introduction to the European Vasculitis Society 3rd International Vasculitis Course (Cambridge) case-based supplement.

    Egan, Allyson C / Smith, Rona M / Jayne, David R W

    Rheumatology (Oxford, England)

    2021  Volume 60, Issue Suppl 3, Page(s) iii1–iii5

    MeSH term(s) Autoimmunity ; Humans ; Vasculitis/diagnosis ; Vasculitis/immunology ; Vasculitis/therapy
    Language English
    Publishing date 2021-06-17
    Publishing country England
    Document type Introductory Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keab331
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Therapeutic dilemmas in relapsing renal ANCA-associated vasculitis.

    Suchanek, Ondrej / Jayne, David R W / Jones, Rachel B

    Rheumatology (Oxford, England)

    2021  Volume 60, Issue Suppl 3, Page(s) iii60–iii62

    MeSH term(s) Acute Kidney Injury/drug therapy ; Acute Kidney Injury/immunology ; Aged ; Anti-Inflammatory Agents/administration & dosage ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Humans ; Immunologic Factors/administration & dosage ; Male ; Prednisolone/administration & dosage ; Recurrence ; Rituximab/administration & dosage
    Chemical Substances Anti-Inflammatory Agents ; Immunologic Factors ; Rituximab (4F4X42SYQ6) ; Prednisolone (9PHQ9Y1OLM)
    Language English
    Publishing date 2021-06-17
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keab178
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated Vasculitis.

    Jayne, David R W / Merkel, Peter A / Bekker, Pirow

    JAMA

    2021  Volume 326, Issue 15, Page(s) 1536

    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Glucocorticoids ; Humans ; Remission Induction ; Rituximab
    Chemical Substances Glucocorticoids ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2021-10-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2021.13873
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply.

    Jayne, David R W / Merkel, Peter A / Bekker, Pirow

    The New England journal of medicine

    2021  Volume 384, Issue 21, Page(s) e81

    MeSH term(s) Aniline Compounds ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Humans ; Nipecotic Acids
    Chemical Substances Aniline Compounds ; Nipecotic Acids ; avacopan (O880NM097T)
    Language English
    Publishing date 2021-05-27
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2104672
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

    Strand, Vibeke / Jayne, David R W / Horomanski, Audra / Yue, Huibin / Bekker, Pirow / Merkel, Peter A

    The Lancet. Rheumatology

    2023  Volume 5, Issue 8, Page(s) e451–e460

    Abstract: Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is characterised by inflammation and destruction of small to medium sized blood vessels. In the previously reported ADVOCATE study, a phase 3 double-blind, double-dummy ... ...

    Abstract Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is characterised by inflammation and destruction of small to medium sized blood vessels. In the previously reported ADVOCATE study, a phase 3 double-blind, double-dummy randomised controlled trial of patients with newly diagnosed or relapsing ANCA-associated vasculitis, the oral selective complement 5a receptor inhibitor avacopan was shown to be non-inferior with regard to remission induction at week 26 and superior with regard to sustained remission at week 52, compared with a prednisone taper in a standard of care regimen. In this Article, we report an in-depth analysis of prespecified and exploratory patient-reported outcomes from the ADVOCATE study, measuring health-related quality of life and health utilities.
    Methods: We did a post-hoc analysis of patient-reported outcome data from the ADVOCATE study (NCT02994927) of patients with newly diagnosed or relapsing ANCA-associated vasculitis. We analysed summary scores and individual domain scores for the prespecified health-related quality of life outcomes from ADVOCATE, which were evaluated at weeks 26 and 52 by use of the Medical Outcomes Survey 36-Item Short Form Health Survey (SF-36) version 2, the EuroQol 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L), and the EQ-5D health utility measure, assessed in the modified intention-to-treat population. We also calculated the Short Form 6 Dimension (SF-6D) score as an additional health utility measure. We evaluated the proportion of patients who reported scores that met or exceeded minimum clinically important differences in health-related quality of life, and we compared scores to normative values (age-specific and sex-specific scores from healthy populations from the USA matched to the protocol population). We also evaluated the proportion of patients who reported scores that met or exceeded minimum important difference in health utility scores.
    Findings: 331 patients were enrolled in the ADVOCATE trial, of whom 166 were in the avacopan group and 165 were in the prednisone standard of care group. In the avacopan group, the mean age was 61·2 years (SD 14·6), 98 (59%) of 166 patients were men, 68 (41%) were women, and 138 (83%) were White; in the prednisone group, the mean age was 60·5 years (14·5), 88 (54%) of 164 patients were men, 76 (46%) were women, and 140 (85%) were White. Patients treated with avacopan received approximately 2500 mg less median total prednisone up to week 52. Least squares means difference from baseline in physical component summary scores were significantly greater in patients in the avacopan group compared with those in the prednisone group at weeks 26 and 52, as well as in five of eight SF-36 domains at week 26 and two of eight SF-36 domains at week 52. The proportion of patients reporting scores equal to or greater than normative values was higher in the avacopan group than in the prednisone group across all SF-36 domains at both week 26 and 52, although the differences were not statistically significant with the exception of the role physical and vitality domains at week 26. Least squares means change from baseline in EQ-5D-5L visual analogue scale, EQ-5D health utility scores, and SF-6D health utility scores were significantly greater at week 52 in the avacopan group compared with the prednisone group.
    Interpretation: Patients with ANCA-associated vasculitis who received avacopan reported statistically significant and clinically meaningful improvements in health-related quality of life at 26 and 52 weeks and in health utility EQ-5D and SF-6D scores at 52 weeks. These patient-reported outcomes complement investigator assessments and support the efficacy of avacopan in patients with ANCA-associated vasculitis with use of lower prednisone doses.
    Funding: ChemoCentryx.
    MeSH term(s) Female ; Humans ; Male ; Middle Aged ; Aniline Compounds ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Antibodies, Antineutrophil Cytoplasmic ; Nipecotic Acids ; Prednisone/therapeutic use ; Quality of Life ; Double-Blind Method
    Chemical Substances Aniline Compounds ; Antibodies, Antineutrophil Cytoplasmic ; avacopan (O880NM097T) ; Nipecotic Acids ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2023-07-24
    Publishing country England
    Document type Randomized Controlled Trial ; Clinical Trial, Phase III ; Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(23)00092-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible?

    Kronbichler, Andreas / Jayne, David R W

    Kidney international

    2018  Volume 94, Issue 6, Page(s) 1045–1047

    Abstract: Despite improved overall prognosis of patients with ANCA-associated vasculitis (AAV), those presenting with impaired renal function remain at risk of developing end-stage renal disease (ESRD). In addition to its role in diagnosis, renal histology ... ...

    Abstract Despite improved overall prognosis of patients with ANCA-associated vasculitis (AAV), those presenting with impaired renal function remain at risk of developing end-stage renal disease (ESRD). In addition to its role in diagnosis, renal histology provides prognostic information that has permitted definition of subgroups with differing risks of ESRD. In this issue, Brix et al. have developed and validated a risk score to predict the probability of ESRD. Against a background of outcome prediction in AAV, this commentary assesses different approaches to histologic risk and to what extent they assist with decisions on patient management.
    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ; Antibodies, Antineutrophil Cytoplasmic ; Glomerulonephritis ; Humans ; Kidney ; Kidney Failure, Chronic
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic
    Language English
    Publishing date 2018-11-22
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2018.10.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Introduction to the European Vasculitis Society 3rd International Vasculitis course (Cambridge, 23-25 September 2019) supplement.

    Smith, Rona M / Jayne, David R W

    Rheumatology (Oxford, England)

    2020  Volume 59, Issue Suppl 3, Page(s) iii1–iii4

    MeSH term(s) Humans ; Vasculitis/diagnosis ; Vasculitis/therapy
    Language English
    Publishing date 2020-04-28
    Publishing country England
    Document type Introductory Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keaa137
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top